Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01975610 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT01975610 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 47 participants.
The verdict
NCT01975610, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
CC-292 is an oral agent that is under clinical development for the treatment of rheumatoid arthritis an autoimmune inflammatory disorder. This study will test the clinical effectiveness and safety of an orally (PO) administered dose of CC-292 compared to placebo in US female patients currently on background Methotrexate (MTX) with active Rheumatoid Arthritis (RA
Interventions
- DRUG Placebo
- DRUG CC-292
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2013-10 |
| Est. Completion | 2016-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01975610
The ClinicalTrials.gov registry entry for NCT01975610 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01975610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01975610 about?
NCT01975610 is a clinical study titled "Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis". CC-292 is an oral agent that is under clinical development for the treatment of rheumatoid arthritis an autoimmune inflammatory disorder. This study will test the clinical effectiveness and safety of an orally (PO) administered dose of CC-292 compared to placebo in US female patients currently on b...
What is the current status of trial NCT01975610?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2013-10. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01975610?
The interventions under investigation include: Placebo (DRUG), CC-292 (DRUG).
Who is sponsoring clinical trial NCT01975610?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.